Bupropion SR for the treatment of postpartum depression: a pilot study
Open accessThe DOI matches its Crossref record.
Abstract
Despite the prevalence of postpartum depression, few studies have assessed the efficacy of antidepressants for the treatment of this disorder. Failure to treat postpartum depression (PPD) places the woman at risk for chronic depression and may have adverse effects on child wellbeing and development. Eight female outpatients aged 18-45 yr were enrolled in an 8-wk open-label trial of bupropion SR for PPD. All patients met DSM-IV criteria for major depression with onset within 3 months of delivery and scored 17 or greater on the Hamilton Depression Rating Scale (HAMD) at baseline. Those with onset of depressive symptoms during pregnancy, psychotic symptoms, or significant medical illness were excluded. Median scores on the HAMD declined from 20.5 (range 15-38) at baseline to 10.0 (range 1-20) at end-point (p<0.05, Wilcoxon signed-ranks test; LOCF). Six out of the eight subjects demonstrated a > or =50% decrease in HAMD scores from baseline; three subjects achieved remission (HAMD score of < or =7) at week 8. Median final dosage of bupropion SR was 262.5 (range 37.5-300). Bupropion SR was well tolerated, and no subjects discontinued treatment as a result of medication side-effects. Bupropion SR represents an effective and well-tolerated antidepressant for the treatment of PPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Psychosocial and psychological interventions for treating postpartum depression
Dennis, C.-L., & Hodnett, E. D. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006116.pub2 · Cited by 565
Bupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
“In a double-blind direct comparison between bupro - pion and fluoxetine, Feighner et al. (48) found no reliable differences between efficacy of bupropion and fluoxetine based on scores from either the HAM-D or CGI scales.”
Nillni, Y. I., Mehralizade, A., Mayer, L., & Milanovic, S. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.004 · Cited by 207
“The OTs examined the use of daily doses of escitalopram, buproprion SR, fluvoxamine, and venlafaxine and found significant improvement in depressive symptoms and high remission rates (Cohen et al., 2001; Misri, Abizadeh, Albert, Carter, & Ryan, 2012; Nonacs et al., 2005; Suri, Burt, Altshuler, Zuckerbrow-Miller, & Fai…”
BackgroundPharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development
Frieder, A., Fersh, M., Hainline, R., & Deligiannidis, K. M. (2019) · CNS Drugs · doi:10.1007/s40263-019-00605-7 · Cited by 156
Metadata
- Authors
- Nonacs, R. M., Soares, C. N., Viguera, A. C., Pearson, K., Poitras, J. R., & Cohen, L. S.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-04-07
- Volume
- 8
- Issue
- 3
- Pages
- 445-449
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2120382660
- Cited by
- 83
- References
- 0
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bupropion SR for the treatment of postpartum depression: a pilot study. https://app.cochat.ai/papers/10.1017/s1461145705005079
- The paper
- Nonacs, R. M., Soares, C. N., Viguera, A. C., Pearson, K., Poitras, J. R., & Cohen, L. S. (2005). Bupropion SR for the treatment of postpartum depression: a pilot study. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145705005079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.